Federated Hermes, Inc. Oric Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$8.04 - $16.03 $1,222 - $2,436	152 New	152 $2,000
Q3 2023 Nov 13, 2023	BUY	$6.05 - $9.28 $949 - $1,456	157 Added 33.62%	624 $3,000
Q2 2023 Aug 14, 2023	BUY	$4.95 - $8.4 $1,603 - $2,721	324 Added 226.57%	467 $3,000
Q1 2023 May 08, 2023	SELL	$4.26 - $6.75 $1,840 - $2,916	-432 Reduced 75.13%	143 $0
Q4 2022 Feb 13, 2023	BUY	$2.41 - $5.89 $339 - $830	141 Added 32.49%	575 $3,000
Q3 2022 Nov 14, 2022	BUY	$3.15 - $5.24 $1,367 - $2,274	434 New	434 $1,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.07 $1,366 - $3,577	-506 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.54 - $16.1 $2,297 - $8,146	506 New	506 $3,000

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.